Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price was up 0.2% on Friday . The stock traded as high as $22.74 and last traded at $22.66. Approximately 9,318,808 shares traded hands during trading, a decline of 77% from the average daily volume of 40,752,861 shares. The stock had previously closed at $22.60.
Analyst Ratings Changes
Several analysts recently weighed in on PFE shares. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and an average target price of $29.17.
Check Out Our Latest Research Report on PFE
Pfizer Trading Up 0.6%
The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $129.30 billion, a PE ratio of 16.12, a P/E/G ratio of 0.64 and a beta of 0.58. The company's 50 day moving average price is $23.72 and its two-hundred day moving average price is $25.40.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the prior year, the business earned $0.82 EPS. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.56%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is 124.64%.
Institutional Investors Weigh In On Pfizer
A number of institutional investors have recently bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the fourth quarter valued at $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC increased its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Finally, GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the 1st quarter worth approximately $27,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Company Profile
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
